RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aveo Pharmaceuticals Stock

Aveo Pharmaceuticals Stocks 2024

Aveo Pharmaceuticals Stocks

32.66 M

Ticker

AVEO

ISIN

US0535883070

WKN

A2P0CL

In 2024, Aveo Pharmaceuticals had 32.66 M outstanding stocks, a 0% change from the 32.66 M stocks in the previous year.

The Aveo Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2026e32.66
2025e32.66
2024e32.66
2023e32.66
2022e32.66
202132.66
202021.4
201915.4
201812.1
201710.6
20166.9
20155.6
20145.2
20135.1
20124.3
20114.1
20102.6
20090.2
20080.2
20070.2
20060.2
20050.2

Aveo Pharmaceuticals shares outstanding

The number of shares was Aveo Pharmaceuticals in 2023 — This indicates how many shares 32.661 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aveo Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aveo Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aveo Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aveo Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aveo Pharmaceuticals Aktienanalyse

What does Aveo Pharmaceuticals do?

Aveo Pharmaceuticals Inc. is a bio-pharmaceutical company focused on the development of new therapies for cancer patients. The company was founded in 2001 in Cambridge, Massachusetts and is listed on the NASDAQ stock exchange under the ticker symbol AVEO. The history of Aveo Pharmaceuticals began with the discovery of a growth factor responsible for the formation of blood vessels in tumors. In collaboration with Harvard Medical School and the Dana-Farber Cancer Institute, the company developed a new drug called Tivozanib, which can block this growth factor. Tivozanib has been tested as a potential treatment for various types of cancer, including kidney cancer, breast cancer, and lung cancer, and is currently in various stages of development. Aveo Pharmaceuticals employs a collaborative business model to involve scientists and researchers in the development of new therapies. The company works together with leading academic institutions and bio-pharmaceutical companies to accelerate and improve the drug development process. Aveo Pharmaceuticals is divided into different divisions that focus on the development of therapies for different types of cancer. These divisions include oncology, which focuses on the development of therapies for solid tumors, as well as hematology, which focuses on the development of therapies for blood cancer. Aveo Pharmaceuticals also has a pipeline of products in various stages of development. These products include both novel drugs and therapies that are already on the market. One of Aveo Pharmaceuticals' most promising products is the drug Tivozanib. Tivozanib is a kinase inhibitor specifically designed for the treatment of kidney cancer. The drug has proven to be effective in clinical trials and could soon be approved by the U.S. Food and Drug Administration (FDA). Tivozanib could improve both the quality of life and the survival rate of kidney cancer patients. Another promising drug from Aveo Pharmaceuticals is Ficlatuzumab, a drug specifically designed for the treatment of solid tumors. Ficlatuzumab targets the hepatocyte growth factor receptor (HGFR), which is overexpressed in various types of cancer such as breast cancer, lung cancer, and pancreatic cancer. The drug is currently in clinical trials and has the potential to become a new treatment option for cancer patients. Over the years, Aveo Pharmaceuticals has received numerous awards and recognitions, including being recognized as one of the "50 Most Innovative Companies in the World" by Technology Review and being included in the "Forbes 200 Best Small Companies in America" ranking. In summary, Aveo Pharmaceuticals is an innovative bio-pharmaceutical company focused on the development of vital therapies for cancer patients. Aveo Pharmaceuticals' collaborative business model has enabled the company to work closely with leading academic institutions and bio-pharmaceutical companies to develop new drugs that could improve the lives of cancer patients. With Tivozanib and Ficlatuzumab, Aveo Pharmaceuticals has two promising drugs in the pipeline that have the potential to change the face of cancer treatment. Aveo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Aveo Pharmaceuticals's Shares Outstanding

Aveo Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Aveo Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Aveo Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Aveo Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Aveo Pharmaceuticals stock

How many stocks are there of Aveo Pharmaceuticals?

The current number of stocks of Aveo Pharmaceuticals is 32.66 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Aveo Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Aveo Pharmaceuticals evolved in recent years?

The number of shares of Aveo Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Aveo Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Aveo Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Aveo Pharmaceuticals pay?

Over the past 12 months, Aveo Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aveo Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aveo Pharmaceuticals?

The current dividend yield of Aveo Pharmaceuticals is .

When does Aveo Pharmaceuticals pay dividends?

Aveo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aveo Pharmaceuticals?

Aveo Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aveo Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aveo Pharmaceuticals located?

Aveo Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aveo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aveo Pharmaceuticals from 8/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/3/2024.

When did Aveo Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/3/2024.

What was the dividend of Aveo Pharmaceuticals in the year 2023?

In the year 2023, Aveo Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aveo Pharmaceuticals pay out the dividend?

The dividends of Aveo Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aveo Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aveo Pharmaceuticals

Our stock analysis for Aveo Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aveo Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.